Skip to main content

Advertisement

Table 1 Baseline Characteristics of Pazopanib Recipients in the PALETTE Trial (ITT Population)

From: Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses

  Pazopanib Arm (n = 246)
Age, y, mean (SD) 54.0 (14.9)
 < 65 y, n (%) 184 (75)
 ≥65 y, n (%) 62 (25)
Female, n (%) 147 (60)
Weight, kg, mean (SD) 71.5 (16.9)
STS subtypes, n (%)
 Leiomyosarcoma 109 (44)
 Synovial sarcoma 25 (10)
 Other STS histologies 112 (46)
Time since initial diagnosis, mo, median (IQR) 26.6 (14.5–46.1)
Time since last progression, mo, median (IQR) 0.7 (0.3–1.1)
Prior lines of therapy, n (%)
 1 110 (45)
 2 or more 136 (55)
  1. SD standard deviation, STS soft tissue sarcoma, IQR interquartile range